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Abstract—Potentialapplicationsoftissueengineeringinregener-
ative medicine range from structural tissues to organs with com-
plex function. This review focuses on the engineering of heart
valve tissue, a goal which involves a unique combination of bi-
ological, engineering, and technological hurdles. We emphasize
basic concepts, approaches and methods, progress made, and re-
maining challenges. To provide a framework for understanding
the enabling scientiﬁc principles, we ﬁrst examine the elements
and features of normal heart valve functional structure, biome-
chanics, development, maturation, remodeling, and response to
injury. Following a discussion of the fundamental principles of
tissue engineering applicable to heart valves, we examine three
approaches to achieving the goal of an engineered tissue heart
valve: (1) cell seeding of biodegradable synthetic scaffolds, (2)
cell seeding of processed tissue scaffolds, and (3) in-vivo repop-
ulation by circulating endogenous cells of implanted substrates
without prior in-vitro cell seeding. Lastly, we analyze challenges
to the ﬁeld and suggest future directions for both preclinical and
translational (clinical) studies that will be needed to address key
regulatoryissuesforsafetyandefﬁcacyoftheapplicationoftissue
engineeringandregenerativeapproachestoheartvalves.Although
modest progress has been made toward the goal of a clinically
useful tissue engineered heart valve, further success and ultimate
human beneﬁt will be dependent upon advances in biodegradable
polymers and other scaffolds, cellular manipulation, strategies for
rebuilding the extracellular matrix, and techniques to characterize
and potentially non-invasively assess the speed and quality of
tissue healing and remodeling.
Keywords—Heart valve remodeling, Engineered tissue heart
valves, Biodegradable scaffold, Decellularized scaffold, Circu-
lating stem cells.
INTRODUCTION
Potential applications of tissue engineering in regen-
erative medicine range from structural tissues (e.g., skin,
cartilage, bone) to complex organs (e.g., heart and other
components of the cardiovascular system, liver, kidney,
pancreas). In each case, there are limitations to conven-
tional surgical approaches and existing prosthetic devices,
serious complications associated with transplantation, and
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critical shortages of available donor tissues. Cardiovas-
cular tissue engineering has primarily considered blood
vessels,58,102,103,104,114,178 myocardium,27,36,74,80,123 and
heart valves.14,119,122,176 This review focuses on the appli-
cation of tissue engineering technology to heart valves.
Currently, adults who undergo replacement of diseased
valves by either mechanical prosthetic or tissue valves (in-
cludingbioprostheticvalves [porcineaorticvalve orbovine
pericardial xenograft], cadaveric allograft, or pulmonary-
to-aortic autograft valves [Ross procedure]) generally have
enhanced survival and quality of life.127 Nevertheless,
each of these valve types has its limitations—in particu-
lar, mechanical valves require anticoagulation to control
thromboembolism, while bioprosthetic and allograft valves
frequently undergo calciﬁcation and structural deteriora-
tion.50,64,146
Advantages of an engineered tissue heart valve would
likely include nonthrombogenicity, infection resistance,
and cellular viability. The design criteria and character-
istics for conventional and tissue engineered replacement
heart valves are summarized and compared in Table 1.T h e
most immediate need for heart valve tissue engineering and
regeneration technology is in the pediatric and young adult
populationinwhichtheresultsofvalvereplacementarenot
as favorable as those in older adults.35,68 Most exciting is
the possibility of growth, repair, and remodeling as a child
recipient matures, thus eliminating the repetitive surgeries
typically necessitated by the inability of a valve substitute
to enlarge as an individual grows. Only autografts (such as
Ross valves transplanted from the pulmonary-to-aortic po-
sition in an individual) presently are viable,120 but the Ross
procedure is technically difﬁcult, risky, only serves a small
patient subset, and has controversial results, including un-
certainty over whether the grafts will grow commensurate
with recipient growth.67
The goal to engineer functional heart valve tissue
presents a unique combination of challenges. Normal heart
valves are vital and dynamic tissues composed of special-
ized cells and extracellular matrix (ECM) that respond
and remodel in response to changes in local mechani-
cal forces.121,143 Approximately 40 million times a year,
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TABLE 1. Design objectives for and characteristics of replacement heart valves.
Feature to optimize Conventional (Mechanical, bioprosthetic) Tissue engineered
Closure of leaﬂets Rapid and complete Rapid and complete
Size of oriﬁce area Less than that of natural valves Better
Mechanical
properties
Stable Stable
Surgical insertion Easy and permanent Easy and permanent
Risk of thrombosis Yes, especially mechanical valves, which require
anticoagulation, causing vulnerability to hemorrhage
No; endothelial surface to inhibit thrombogenesis
Risk of structural
dysfunction
Degradation of synthetic materials rare with mechanical
valves
Resistant to degradation and calciﬁcation
Tissue degradation and calciﬁcation of leaﬂets with
bioprosthetic valves
Risk of Infection Ever present Resistant to infection
Viability No Yes, able to repair injury, remodel, and potentially
grow with patient
opening and closing of the leaﬂets induces repetitive
changes in the shape, dimensions, and stress of the leaﬂets
and supporting valvular structures (Fig. 1).147 A successful
tissue engineered valve and its components must not only
accommodate those deformations but also have ongoing
strength, ﬂexibility, and durability, beginning at the instant
of implantation and continuing indeﬁnitely thereafter, pos-
sibly despite an evolving tissue architecture.
This review provides a contemporary analysis of heart
valve tissue engineering and regeneration, emphasizing the
evolving understanding of heart valve biology, the promise
and difﬁculties demonstrated by in-vivo studies done to
date, and the critical challenges that will be encountered in
translating the potential of this exciting therapeutic modal-
ity from the laboratory to the clinical realm. To put the
technology and the evolving enabling science into context,
webeginbyexaminingthecomplexanddynamicstructural
components that are needed to accomplish normal heart
valve function, biomechanics, physiological tissue main-
tenance, homeostasis, and ongoing health. Our discussion
of the basic principles of tissue engineering summarizes
current principles of scaffolding and cell sourcing. Sub-
sequently, we examine three potential approaches to the
ﬁeld of tissue-engineered heart valves: (1) cell seeding of
biodegradable synthetic scaffolds, (2) cell seeding of pro-
cessed tissue scaffolds, and (3) in-vivo repopulation by cir-
culating endogenous cells of implanted substrates without
prior in-vitro cell seeding. Finally, we analyze challenges
to the ﬁeld and suggest future directions for both preclin-
ical and translational (clinical) studies that will be needed
to address key regulatory issues for safety and efﬁcacy
of the application of tissue engineering and regenerative
approaches to heart valves. Our primary goal is to stim-
ulate thinking in the ﬁeld by introducing concepts such
as outcome criteria, biomarkers, molecular imaging, prod-
uct release criteria, questions raised by the integration of
engineeredheartvalveswiththehosttissues,anduncertain-
ties engendered by patient-to-patient heterogeneity in key
biological processes such as tissue remodeling capability.
Our discussion in this paper underscores that the devel-
opment and application of innovative approaches to repair
and regenerate damaged or diseased heart valves requires
the integration of numerous biological, engineering, and
technological principles.
HEART VALVE FUNCTION AND STRUCTURE
Healthy native heart valves maintain unidirectional
blood ﬂow via an extraordinarily dynamic functional struc-
ture with several key characteristics: viability, sufﬁcient
strength to withstand repetitive and substantial mechanical
stress, and ability to adapt and repair injury by connective
tissue remodeling. A rational approach to heart valve tissue
engineering depends on a thorough understanding of the
complex normal functional elements and their coordinated
interactions (Table 2).185 For the trileaﬂet semilunar valves
(aortic and pulmonary), the important structures are the
cusps (which avoid prolapse by substantial coaptation), the
commissures, and the supporting structures in the aortic
and pulmonary roots. For the atrioventricular valves (mitral
and tricuspid), the key components are the leaﬂets, com-
missures, annulus, chordae tendineae, papillary muscles,
and atrial and ventricular myocardium. Valve leaﬂets and
cusps have few and only focal blood vessels (vessels may
be present in the proximal portion near the myocardium),
likely because valves cusps and leaﬂets are sufﬁciently thin
tobenourishedpredominantlybydiffusionfromtheheart’s
blood. Valve leaﬂets and cusps also have nerves, but their
signiﬁcance is uncertain.87
The four cardiac valves have microstructural similari-
ties; however, the aortic valve best illustrates the essential
features and serves as a paradigm for microstructural and
cellular adaptation to functional requirements. The aortic
valve is the most frequently diseased and also commonlyHeart Valve Tissue Engineering 1801
FIGURE 1. Specialized ECM enables dynamic aortic valve function. (a) Photograph of the aortic valve in open and closed position
(from the aorta). (b) Aortic valve histology emphasizing trilaminar structure and presence of valvular interstitial and endothelial
cells. (c) Biomechanical cooperativity between elastin and collagen during valve motion. (d) Schematic depiction of layered aortic
valve cuspal structure and conﬁguration of collagen and elastin during systole and diastole. (a) and (b) reproduced by permission
from Schoen FJ. “Valvular heart disease: General principles and stenosis,” IN: Cardiovascular Pathology, 3rd Ed, Silver MD,
Gotlieb AI, Schoen FJ (eds.), WB Saunders 2001, pp. 402–442; (c) and (d) reproduced by permission from Schoen FJ. Aortic valve
structure-function correlations: Role of elastic ﬁbers no longer a stretch of the imagination. J Heart Valve Dis 6: 1–6, 1997.
TABLE 2. Key structural elements of heart valves.
Element Sub-structure Function
Extracellular matrix Collagen Provides strength and stiffness to maintain coaptation during diastole, when
cusp has maximal area
Elastin Extends in diastole; contracts in systole to minimize cusp area
Glycosaminoglycans Accomodates shear of cuspal layers, cushions shock during valve cycle
Cells Interstitial Synthesize ECM; express MMPs and TIMPs that mediate matrix remodeling
Endothelial Maintain nonthrombogenic blood-tissue interface; regulate immune and
inﬂammatory reactions
Blood vessels Few and focal; valve cusps and leaﬂets sufﬁciently thin to be nourished by
diffusion from the heart’s blood
Nerves Present, with uncertain function
Other principles Corrugations Accordian-like folds in cusps; allows cuspal shape and dimensions to vary with
cardiac cycle
Crimp Microscopic collagen folding, allows lengthening at minimal stress
Anisotropy Permits differences in radial and circumferential extensibility
Cords Macroscopic collagen alignment; transfers forces from cusps to aortic wall1802 K. MENDELSON AND F. J. SCHOEN
transplanted. The aortic valve cusps undergo substantial
changes in shape and dimension during the cardiac cycle
(see Fig. 1a). Microscopically, the aortic valve is composed
of three distinct layers: (1) the ventricularis closest to the
inﬂow surface, rich in elastin, (2) the ﬁbrosa closest to
the outﬂow surface, primarily composed of densely packed
collagen, and (3) the centrally located spongiosa, largely
composed of glycosoaminoglycans (GAGs). Together, col-
lagen, elastin, and GAGs comprise the valvular ECM (see
Fig. 1b). Studies of normal, pathological, and substitute
valves have demonstrated that the principal determinant
of valve durability is the valvular ECM, whose quan-
tity and quality depend on the viability and function of
valvular interstitial cells (VIC).145 Recent research sug-
gests that cell-matrix interactions in heart valves are highly
stress-dependent and likely reciprocal. In vivo, heart valve
leaﬂets experience a dynamic and complex mechanical
stress state during every cardiac cycle: sheer stress due
to blood ﬂow (open valve), ﬂexure (opening and clos-
ing), and tension (closed valve).92,93 Forces acting on
the valve at the macroscopic level (pressure, sheer stress,
and tension) are translated into speciﬁc biomechanical re-
sponses at the tissue level (collagen uncrimping, reorien-
tation, and ﬁber compaction) which are transduced into
a VIC response at the cellular level (with intracellular
signaling events leading to changes such as increased al-
pha smooth muscle actin (α-SMA) expression, increased
VIC stiffness, and increased ECM biosynthesis). Indeed,
the higher absolute pressure and transvalvular pressure
gradients on the left side of the heart impose larger lo-
cal tissue stress on the VICs than those on the right
side, which leads to higher VIC stiffness (through α-
SMA content) and collagen biosynthesis in the left-sided
valves.94
Complex microstructural rearrangements and several
specializations of collagen accommodate the cyclical pres-
sureﬂuctuationsduringthecardiaccycle.143 Collagenﬁbers
in a planar orientation in the ﬁbrosa comprise the strongest
portion of the leaﬂet that is responsible for bearing dias-
tolic stress. GAGs in the spongiosa probably serve pre-
dominantly as a shock and shear absorber. The large cuspal
deformation during the cycle between systole and diastole
is facilitated by biomechanical cooperativity between col-
lagen and elastin (see Fig. 1c). Collagen ﬁbrils are inelastic
and incapable of supporting large strains; they therefore
have adaptations (macroscopic corrugations and micro-
scopic crimp) that permit collagen stretching at minimal
stress by unfolding (Fig. 1d). During valve opening, elastin
stretches during extension of collagen crimp and corru-
gations. When the valve is closed, the collagen is fully
unfolded and the load is shifted from elastin to collagen;
elastin restores the contracted conﬁguration of the cusp
during systole.
Two types of cells are present in the aortic valve: en-
dothelial cells covering the surface and interstitial cells
withvariablepropertiesofﬁbroblasts,smoothmusclecells,
and myoﬁbroblasts in the interior (see Fig. 1b).1,121,168,169
Like endothelial cells elsewhere in the circulation, valvu-
lar endothelial cells (VEC) maintain a nonthrombogenic
blood-tissue interface and regulate immune and inﬂamma-
tory reactions. Nevertheless, endothelial cells isolated from
different vascular and valvular sources display differences
in gene expression and other properties (endothelial cell
heterogeneity).21 Indeed, heart valve endothelial cells are
different from those in the aorta.16,17 For example, in re-
sponse to mechanical stress, porcine aortic valve endothe-
lial cells align perpendicular to ﬂow whereas endothelial
cells from the aorta align parallel to ﬂow and their gene
expression is different from that of aortic endothelial cells
exposed to the same mechanical environment. These dif-
ferences suggest a unique phenotype of VEC not mim-
icked by vascular cells and could have implications for
cardiovascular cell biology and cell-source considerations
fortissue-engineeredheartvalves.Moreover,differenttran-
scriptionalproﬁlesareexpressed bytheendothelium onthe
aortic side versus ventricular side of normal adult pig aor-
tic valves.155 The reasons for these differences are not yet
known.
VIC, the most numerous valvular cell type, synthesize
ECM and express matrix degrading enzymes, metallopro-
teinases (MMPs), and their inhibitors (TIMPs) that medi-
ate matrix remodeling.1,169 Moreover, VIC comprise a dy-
namic population of resident cells of diverse and dynamic
phenotypes, in a spectrum that ranges from ﬁbroblast-like
to myoﬁbroblast-like; their phenotype is regulated by en-
vironmental conditions.1,25,121,168,169, We and others have
evaluated VIC phenotypes in normal and diseased human
valves. In adult heart valves in situ, VIC are quiescent
and display a ﬁbroblast-like phenotype, characterized by
the presence of vimentin (intermediate ﬁlaments), and very
low levels of α-SMA, MMP-13 (proteolytic enzymes), and
SMemb (non-muscle myosin heavy chain). Indeed, only
2–5% of normal adult VIC express α-SMA, which is a
marker of myoﬁbroblast-like function.1,121,142,148 Myoﬁ-
broblasts are activated ﬁbroblasts that synthesize and re-
model the specialized ECM, facilitate tissue remodeling
and wound healing, and play a pathological role in ﬁ-
brotic disease.99,148 In contrast, as demonstrated by pre-
vious in-vitro studies using isolated cells cultured from
heart valves, 56–78% of cells are α-SMA-positive.169 This
suggests that removal of cells from the environment of the
intact valve (i.e., in culture) or their manipulation stimu-
lates VIC. Moreover, treatment of isolated VICs with TGF-
β strongly activates interstitial cells to the myoﬁbroblast
phenotype.177
Biomechanical and biochemical factors play an impor-
tantandpotentiallysynergisticroleindeterminingthelocal
homeostatic environment of the aortic VIC. As demon-
strated in in-vitro studies, mechanical stimulation (ten-
sion) and cytokine stimulation (TGF-β1) were found toHeart Valve Tissue Engineering 1803
synergistically alter the contractile (α-SMA) and biosyn-
thetic (heat shock protein, Hsp 47) proteins of aortic VICs
toagreaterextentthaneachfactoralone.93 Theneedforme-
chanical stimulation and/or cytokines and potentially other
soluble factors for the maintenance of appropriate cellular
biosyntheticactivitywillbeanimportantinﬂuenceontissue
engineering efforts.
HEART VALVE DEVELOPMENT, MATURATION,
ADAPTATION, AND REPAIR
A thorough understanding of developmental biology,
physiology, and pathophysiology of heart valves will likely
inform tissue engineering. Indeed, some of the processes
and regulatory pathways active in valvular development
and maturation may be recapitulated in tissue engineered
valves. During embryological development, the three germ
layers–ectoderm, endoderm, and mesoderm–give rise to
cells that differentiate to form the body’s tissues and com-
plex organs. The heart develops primarily from the embry-
onic layer called mesoderm.160 The initial commitment of
mesodermal precursor cells to a cardiac lineage depends
on complex signaling pathways.106 Cardiac myocytes be-
come organized into a linear heart tube that subsequently
undergoes looping.174 Growth of the looped heart tube
and development of septa leads to the multichambered
heart.
Duringcardiacdevelopment,thevalvecuspsandleaﬂets
originate as outgrowths (known as endocardial cushions)
from mesodermal derived connective tissue called mes-
enchyme.30 Endothelial cells lining the inside surface
of the cushion forming area undergo an epithelial-to-
mesenchymal transdifferentiation (EMT) and migrate from
the blood-contacting internal heart surface deep into the
connective tissue of the subendocardium (called cardiac
jelly)tobecomeprecursorsofmatureVICs.5 Widespreadin
embryological development, epithelial mesenchymal tran-
sitions comprise a series of cell–cell and cell-matrix in-
teractions that release epithelial cells from a surface and
confer the ability to move through three dimensional ECM
and synthesize ECM.124 The newly formed mesenchymal
cellsremodelthecushionsintoleaﬂetsandcusps.Evidence
for EMT is provided by mesenchymal cellular expression
of α-SMA, a marker that is not typically expressed by en-
dothelial cells.31,110 Numerous signaling pathways, growth
and transcriptional factors (including vascular endothelial
growth factor [VEGF], nuclear factor in activated T cells
[NFATc1], and Notch) regulate the process of heart valve
formation.5,9,43,78
We studied the subsequent maturation and evolution of
human semilunar valves in fetuses, neonates, children, and
adults.1 We demonstrated that fetal valves contain imma-
ture activated cells and are dynamic and adaptable struc-
tures; the architecture, collagen content, and organization
were immature compared with that of adult valves. Dur-
ing valve development and maturation, fetal VIC have a
myoﬁbroblast-like phenotype, characterized by expression
of α-SMA, MMP-13, and SMemb, and continuously re-
model the ECM. The cells become quiescent in the normal
valve post-natally, suggesting progressive adaptation to the
prevailing hemodynamic environment. Moreover, the cell
densityprogressivelydecreases(bynearly90%)throughout
life.
The role of myoﬁbroblasts in valvular wound healing,
adaptation, and remodeling is best illustrated by compar-
isons of normal, diseased, autograft, and tissue engineered
valves.121 In conditions of disease (e.g., myxomatous mi-
tral valve),117 adaptation (early pulmonary-to-aortic auto-
graft),120 or remodeling (tissue engineered valves in-vitro
and in-vivo),118 VICs have an activated myoﬁbroblast phe-
notype, similar to that of fetal valves. Normal and patho-
logicalcardiacvalvesrespondtoenvironmentalconditions,
such as mechanical loading, by cell activation and matrix
remodeling. In contrast, following return of a stable equi-
librium of mechanical state in development, adaptation, or
remodeling, VIC return to their normal quiescent ﬁbrob-
last phenotype, as exempliﬁed by late pulmonary-to-aortic
autografts (>3 years postoperative) and tissue engineered
valves implanted in-vivo. Therefore, heart valves respond
to environmental change via reversible phenotypic modu-
lation of their resident VICs.
SCAFFOLDS FOR TISSUE ENGINEERING:
GENERAL CONCEPTS
A widely accepted paradigm of tissue engineering com-
prises (1) a scaffold, that is pre-seeded with (2) cells,f o l -
lowed by (3) an in-vitro stage of tissue formation typically
conducted in a bioreactor (that recapitulates a physiolog-
ical metabolic and mechanical environment), and subse-
quently, following implantation of the construct, (4) an in-
vivostageoftissuegrowthandremodeling(Fig.2,Pathway
A).77 The key pathophysiological processes occurring dur-
ing the in-vitro and in-vivo phases are cell proliferation
and migration, ECM production and organization, scaffold
degradation, and tissue remodeling. The in-vivo but not
the in-vitro phase can involve recruitment of the recipi-
ent’s inﬂammatory cells. The resulting tissue engineered
construct will likely contain some combination of seeded
and/or recipient-derived new cells. An alternative pathway
(Fig. 2, Pathway B) utilizes an unseeded scaffold that in-
corporates biological “information” designed to attract and
direct the formation of circulating endogenous precursor
cells (potentially both endothelial and mesenchymal) in-
vivo.Bothofthesepathwaysareconsideredindetailinsub-
sequentsectionsofthispaper.Moreover,hostinﬂammatory
cellsmayplayaroleinthein-vivophaseofeitherapproach.
In the following sections we examine the characteristics of
biodegradable synthetic scaffolds and natural allograft or
xenograft scaffolds; a composite biodegradable polymer1804 K. MENDELSON AND F. J. SCHOEN
Engineered Tissue and
Derivatives of Seeded Cells and/or New Cells 
In vivo remodeling
Pathway A Pathway B
Pathway B: Modified Paradigm
•Implant appropriate scaffold in-vivo
•Enhance release, targeted recruitment, 
adhesion, migration, proliferation, 
differentiation, and function of desired cell 
populations
•Avoid unwanted recruitment
Pathway A: Conventional Paradigm
•Combine appropriate cells and scaffold
•Grow valve in-vitro in a bioreactor that 
provides mechanical and metabolic support
•Implant in anatomic site in-vivo
In-vivo Phase
Circulating Precursor 
Cells (Endothelial
and Mesenchymal) Scaffold
Exogenous 
Cells
Elements
Construct
In vitro maturation 
in a bioreactor
In-vitro Phase
FIGURE 2. Tissue engineering paradigms. (Pathway A) The conventional paradigm of tissue engineering comprises a scaffold that
is seeded with cells, an in-vitro stage of tissue formation typically conducted in a bioreactor, and an in-vivo stage of tissue growth
and remodeling. The key pathophysiological processes occurring during the in-vitro and in-vivo phases are cell proliferation,
ECM production and organization, scaffold degradation, and tissue remodeling. The resulting tissue engineered construct will
contain some combination of seeded and/or new cells. A modiﬁed paradigm (Pathway B) might utilize an unseeded scaffold that
is fabricated with biological “information” designed to attract and provide a suitable substrate for differentiation of circulating
precursor cells in-vivo.
with collagen or other natural material may also be consid-
ered (Table 3).
Synthetic Scaffolds
Synthetic polymeric scaffolds generally have well con-
trolled and easily reproduced properties. Ideally, a tissue
engineered scaffold should be biocompatible, resorbable,
have a highly porous macrostructure (necessary for cell
growth, nutrient supply and waste removal) and a surface
conducive to cellular attachment and potentially migra-
tion, proliferation, differentiation, matrix formation and/or
remodeling.Abioresorbablescaffoldservesasatemporary
matrix until the seeded cells are capable of producing their
TABLE 3. Comparative analysis of scaffolds.
Synthetic scaffolds Natural scaffolds
Advantages Control of material structure and properties (e.g.
pore size, stability, degradation rate)
Maintain architecture of the native tissue
(potentially valve)
Easily reproduced Maintain biological information (e.g.,
reactive sites, growth factors)
Resorbable Potentially resorbable
Disadvantages Difﬁculty in controlling cell adhesion and tissue
reorganization
Decellularization may alter physical
properties
Inﬂammation due to incomplete polymer
degradation or lack of biocompatibility
Difﬁculty of cell penetration into interior
Space formerly occupied by polymer and its
interstices is replaced by ﬁbrosis/scar
May induce immunologic reaction
Limited perfusion to deep cells Potential for calciﬁcationHeart Valve Tissue Engineering 1805
own matrix proteins; the chemical and physical properties
and the rate of degradation are generally tailored to the ap-
plication and the rate of new tissue evolution.41,53,69,83,100
Polyglycolic acid (PGA) and polylactic acid (PLA) and
their copolymers are currently the synthetic, biodegradable
polymers most widely considered for tissue engineering
applications. PGA is a highly crystalline, linear, aliphatic
polyester, with a high melting point and low solubility
in organic solvents. PGA was used as the ﬁrst totally
synthetic resorbable suture, commercially available under
the trade name “Dexon” since 1970. PGA is rapidly re-
sorbable; thus, Dexon sutures tend to lose their mechanical
strength rapidly, usually within 2 to 4 weeks after implan-
tation. Copolymers of the hydrophilic PGA with the more
hydrophobic PLA increase the range of material proper-
ties and hence possible applications; for example, the ad-
dition of PLA limits the water uptake and reduces the rate
of hydrolysis (the predominant model of degradation) as
compared to PGA alone. Considered safe, nontoxic, and
biocompatible, these polymers are used successfully in a
number of approved medical implants.48
The use of a synthetic scaffold introduces challenges in
theregulationofcelladhesionandthree-dimensionaltissue
reorganization since such materials are usually isotropic
and ECM proteins are not usual constituents of synthetic
polymers. For example, PGA, PLA, and their copolymers
are generally considered poor substrates for cell growth
in-vitro.71 Therefore, bioactive synthetic biomaterials are
being developed for use as three-dimensional microenvi-
ronments that mimic ECM function.84,85 Recent advances
include nanoﬁbrillar networks formed by self-assembly of
small molecules and artiﬁcial ECM networks from pro-
tein polymers or synthetic polymers that present bioactive
ligands and respond to cell-secreted signals to enable re-
modeling.115
An especially attractive concept is that of smart bio-
material scaffolds, which carry spatial and chemical in-
formation that affects cellular function and/or responds to
changes in the environment.76 Smart scaffolds are exempli-
ﬁed by biodegradable elastic shape-memory polymers that
predictably alter their shape with changes in temperature79
and polymers that transition between hydrophobic and hy-
drophilic states in response to electric potential.2,75 More-
over,normaltissueculturedishesgraftedwithatemperature
sensitive polymer PIPAAm (poly N-isopropylacrylamide)
respond to temperature changes, which alter the adhesion
properties of cells to this matrix. At elevated temperatures
(above 37◦C), the dish surfaces are relatively hydrophobic
and cells attach, whereas at lower temperatures (20◦C) the
polymer surface becomes hydrophilic and swells, forming
a hydration layer between the dish surface and the cultured
cells. The cells along with their framework ECM sponta-
neously detach and maybe harvested as intact sheets.186 As
the technology develops, smart scaffolds may prove impor-
tant to applications of stem cells in tissue engineering; for
example, a new three dimensional material with the ability
to direct the differentiation of neural progenitor cells into a
speciﬁc lineage without the help of growth factors has been
reported.154
Tissue engineered biomaterial constructs must also ex-
hibitmechanicalandstructuralpropertiescomparabletothe
native tissue they replace, including dynamic anisotropic
behaviors optimized for tissue speciﬁc function, from the
time of implantation of a construct through the lifetime of
therecipient.Thisimpliescentralrequirementsofrelatively
constant mechanical properties despite potentially consid-
erabletissueremodelingandscaffoldresorption.Moreover,
mechanical anisotropy (certainly a characteristic of the nat-
ural valves)92 may be desirable; towards this end, elec-
trospun scaffolds were fabricated which exhibited highly
anisotropic mechanical properties that resembled native
pulmonary heart valve cusps.136
Potential undesirable features of synthetic scaffolds in-
clude local tissue inﬂammation owing to the foreign body
reaction and slow and/or incomplete polymer degradation.
As the scaffold degrades, the space formerly occupied by
a polymer and its interstices is progressively ﬁlled by cells
andECMwhichmayeventuateinﬁbrosis(scar)thatpoorly
resembles specialized native tissue and may contract and
distort during maturation. In some cases, cells on the scaf-
fold periphery are healthy and resemble native differenti-
ated parenchymal (i.e., function-speciﬁc) tissue whereas
cells at the interior become necrotic due to restricted
deep delivery of oxygen and nutrients, and removal of
wastes.
Natural Scaffolds
Alternative to synthetic scaffolds, natural scaffolds usu-
ally comprise pure ECM components (such as collagen
or ﬁbrin) or decellularized but otherwise intact allograft or
xenograft tissue(suchas heart valve orsmall intestinalsub-
mucosa). In cardiovascular tissue engineering, multi-step
static seeding methods have been most commonly used;
alternatively, efﬁcient single step seeding may be achieved
viacellularencapsulationincollagenandﬁbringels.Colla-
gen based constructs seeded with vascular smooth muscle
and/orendothelialcellshavebeenutilizedtogeneratetubu-
lar blood vessels,178 one-dimensional strings to serve as a
component of composite aortic valve cusps150 or chordae
tendineae151 and molds for heart valve leaﬂets.171 Cells
entrapped in collagen gels contract and compact the gels
in a process similar to the contraction of a wound dur-
ing healing, thus increasing their density and enhancing
their properties.170 Alternatively, cells can be encapsulated
in an autologous ﬁbrin gel which initially serves to ob-
tain uniform cell distribution and to improve the seeding
efﬁciency.66,97,134,187 With gel encapsulated cells, newly
synthesized ECM accumulates in the immediate extra-
cellular space, rather than diffusing into the surrounding1806 K. MENDELSON AND F. J. SCHOEN
medium.187 Reported limitations of the encapsulated cell
approach to tissue engineering include excessive shrink-
age of the gel/cell construct,66 and the possibility that the
entrapped cells become necrotic or apoptotic.166 In one in-
vitro study, cells encapsulated in a ﬁbrin gel were seeded
onto a synthetic PGA scaffold to optimize tissue formation
andorganization.Followingﬁbrindegradation,theunderly-
ing synthetic scaffold contributed to the structural integrity
of the developing tissue.97 Additionally, hyaluronan, a vis-
coelastic and broadly biocompatible material that plays a
role during embryonic cardiac development, is also being
explored as a potential ECM scaffold material.88,129
Some investigators favor enzymatically decellularized
tissue as a natural scaffold. This treatment is done to de-
crease antigenicity and the risk of calciﬁcation (both of
whichareenhancedbycellsandtheirdebris).Thehopewith
a decellularized scaffold is that preseeded or endogenous
circulating cells can repopulate such a scaffold. A decellu-
larized allograft or xenograft tissue scaffold may best serve
as a template for cellular attachment and retain many of the
mechanical and structural properties of native tissue such
as tensile strength and unique ECM composition.54
Decellularizedporcinesmallintestinalsubmucosa(SIS)
has been studied extensively as a natural resorbable scaf-
fold material that does not require cell seeding.7 In both
animal and human clinical studies, SIS was rapidly remod-
eled by the host tissue.133 Useful in implants ranging from
particulate material related to the bladder,182 to sheets that
might be used to repair the infarcted left ventricle,132 SIS
has exhibited good vascularization and tissue growth with-
out excessive inﬂammation and foreign body reaction. The
success of SIS has been attributed to its intrinsic ECM
proteins, GAGs, cytokines, and growth factors (VEGF and
TGF-β).130
CELLS FOR TISSUE ENGINEERING:
GENERAL CONCEPTS
Whiletheultimategoaloftissueengineeredheartvalves
is to recapitulate the matrix and cells found in native tissue,
there exists variability in potential strategies and sources
of cells. The predominant paradigm provides cell-seeded
scaffolds (biodegradable or natural) with the ingredients
and environment to form tissue and mature in-vitro in a
bioreactor, in order to generate a construct which is then
implanted in-vivo in the desired anatomic location (recall
Fig. 2, Pathway A). Potential cellular sources for seed-
ing of scaffolds to fabricate heart valves include differenti-
atedtissue-speciﬁccells(suchasendothelialand/orsmooth
muscle cells91) and stem cells that may be autologous or
allogenic. In a clinical study, an in-vitro endothelialization
procedure, in which femoropopliteal arterial grafts com-
posed of expanded polytetraﬂuoroethylene (ePTFE) were
conﬂuentlylinedwithculturedautologousendothelialcells
before implantation, was assessed for its ability to improve
thelong-termpatencyoftheseprostheticbypassgrafts.The
results(regrettablynotcomparedwithconcurrentunseeded
control grafts) suggested that autologous endothelial cell
lining improved the patency of these small-diameter vas-
cular grafts.26 Another option is to harness the potential of
endogenouscellsbyutilizingdecellularizedbiologicalscaf-
folds that contain intact ECM and other chemical signals
necessary to recruit the appropriate cell populations (recall
Fig. 2, Pathway B and see below); unseeded scaffolds that
could attract endogenous cells in-vivo to the site of im-
plantation might permit bypassing the in-vitro stage of cell
seeding, by facilitating repair by endogenous cells. Nev-
ertheless, presently used tissue heart valve replacements
do not endothelialize from circulating blood to a degree
sufﬁcient to provide functional beneﬁt. This holds true for
both glutaraldehyde-pretreated porcine valves,59 in which
the barrier to endothelialization may result from toxicity
induced by residual glutaraldehyde,37 and cryopreserved
allograft heart valves.95
The unique properties of stem cells, such as multipo-
tency and capacity for self-renewal, make them attractive
cells for tissue engineering.22,46 Stem cells are found in
the bone marrow of adults, including hematopoietic stem
cells (which form the mature blood cells), endothelial stem
cells (endothelial progenitor cells, which form components
of the cardiovascular system), and mesenchymal stem cells
(which form bone, cartilage, muscle, fat, and ﬁbroblasts).
Bone marrow-derived adult somatic stem cells are an at-
tractive cell source because they are multipotential cells,
in principle capable of differentiation, transformation, and
regeneration. We will not discuss stem cells of embryonic
originowing tothe complicated scientiﬁc ethical and moral
issues surrounding their usage. Bone marrow comprises an
ideal cell source for tissue engineering because its cells are
easilyaccessible,itsprimaryisolateisacellsuspensionthat
is easier to process and less prone to contamination than
solid tissue, and bone marrow will likely be the primary
source of cells for endogenous repopulation.164 Through-
out post-natal life, both bone marrow-derived and organ-
resident adult stem cells continuously regenerate some tis-
sues (such as skin epithelium, intestinal epithelium, blood
cells, and liver when stimulated). Nevertheless, increasing
evidence suggests that the heart and the brain can regener-
ate some of their mass, defying the conventional wisdom
that these organs cannot replenish cells lost as a result of
maturation, senescence, and injury.33,81
Endothelial progenitor cells (EPCs) are bone marrow-
derived hematopoietic stem cells capable of differentiating
into the endothelial cells that line the blood vessels and
cardiac valves.56,61,125,173 EPCs maintain vascular home-
ostasis by promoting reendothelialization after endothelial
injury and neovascularization after tissue ischemia. En-
dothelial progenitor-derived cells obtained from peripheral
blood have been expanded in-vitro and seeded on a threeHeart Valve Tissue Engineering 1807
dimensional biodegradable PGA-PLLA scaffold. When
seeded alone, they maintained an endothelial phenotype
for the entire six-week duration of implantation and when
co-seeded with smooth muscle cells, the endothelial pro-
genitor derived endothelial cells formed microvessels on
the scaffold.184 EPCs obtained from peripheral blood have
also been used to line small diameter vascular grafts.70
Mesenchymal stem cells (MSCs), have the potential for
differentiating into osteogenic, chondrogenic, adipogenic,
and myogenic lineages.113,116 These can be isolated from
adult bone marrow and represent another adult stem cell
population that can be used as a cellular source in tissue
engineering.86,90,112 The concept of continuous replace-
ment of connective tissue with bone marrow mesenchymal
stem cells parallels the known continuous replacement of
bloodbybonemarrowhematopoieticcells.CulturedMSCs
display the spindle shape morphology characteristic of my-
oﬁbroblasts and express cell markers characteristic of VIC.
Upon implantation, these cells retain proﬁles identical to
those seen in-vitro. Following myocardial infarction in a
mouse model, injected MSCs improve recovery of the in-
farcted tissue and were thought to differentiate into car-
diac myocytes, endothelial cells, and vascular smooth mus-
cle cells.107 Marrow progenitor cells or multipotent adult
progenitor cells (MAPCs) have many attributes of MSCs
but they are reported to expand indeﬁnitely (compared to
1 million fold expansion of MSCs) and may have lin-
eage potential that includes ectodermal and endothelial cell
types, making them similar to embryonic stem cells.65
BIOREACTORS FOR TISSUE ENGINEERING
Mechanical stimulation through the use of bioreac-
tors during in-vitro tissue development is widely uti-
lized in cardiovascular tissue engineering for improving
tissue formation, organization, and function. The biore-
actor exposes the developing tissue to mechanical con-
ditioning, primarily through cyclical ﬂow and pressure
changes that mimic physiological conditions. Bioreac-
tors have been developed that use ﬂow52,101,158,181 and
strain103,161 as their main mechanical cues to engineer
blood vessels and heart valves. For the engineering of
heart valves, a diastolic pulse duplicator bioreactor has
been developed to mimic only the diastolic phase of the
cardiac cycle, resulting in dynamic tissue straining.96 Ad-
ditionally, electrical stimulation (designed to mimic native
excitation-contraction coupling) has been used as a cue
to enhance the structure and function of pulsatile my-
ocardium in-vitro.123 The optimal conditioning protocol
depends on numerous parameters such as the sensitivity of
the cell phenotype to mechanical cues, the scaffold used,
the transfer of the mechanical cues from the scaffold to the
cells, and the magnitude and type of mechanical cues.
KEY IN-VIVO STUDIES IN HEART VALVE
TISSUE ENGINEERING
Many published studies have used in-vitro methods to
investigate critical variables and demonstrated “proof-of-
principle” of important concepts in tissue engineering ger-
mane to heart valves. Only a few key studies have been
conducted using synthetic and natural scaffolds in animal
models (Table 4). Early studies focused on the design of
individual valve leaﬂets188 whereas later studies emphasize
design of complete valved conduits. In this section, we
focus on studies in which scaffolds seeded in-vitro were
implanted in-vivo. Following this section, we discuss the
possibilitythattherecipientcanprovideallthecellsneeded
to populate and/or remodel a scaffold to yield a functional
heart valve in-vivo.
Implant Studies Using Synthetic Scaffolds Seeded In-Vitro
In this approach a bioabsorbable polymer provides
a temporary scaffold until cells seeded in-vitro produce
their own matrix proteins (see Fig. 2, Pathway A). The
biodegradable polymer PGA and related compounds have
been used as biodegradable synthetic polymer scaffolds
because this polymer (albeit with suboptimal mechanical
properties) is well characterized and approved by the FDA
in sutures and other devices for human implantation. In one
oftheearliestexperimentsintheﬁeld,anisolatedtissueen-
gineeredheartvalveleaﬂetwasimplantedinthepulmonary
position of sheep using a PGA scaffold seeded with vascu-
lar wall cells.152,153 Histologic evaluation of the constructs
showed development of an ECM, endothelialization of the
surface, and scaffold remodeling. While this preliminary
experiment showed that a tissue engineered valve leaﬂet
constructed from its cellular components can function in
the pulmonary valve position, the resultant engineered tis-
sue heart valve cusps were thicker, stiffer, and less pliable
than native valves.
To alleviate the problem of scaffold thickness and
rigidity, Hoerstrup et al.52 designed a scaffold compos-
ite that combined PGA with the strong, ﬂexible poly-4-
hydroxybutyrate (P4HB) formed in the conﬁguration of a
trileaﬂet heart valve. P4HB is added to prolong mechanical
integritybecausePGAdegradesfasterthanP4HB(approxi-
mately 4 weeks versus 8 weeks respectively). This scaffold
was seeded with differentiated autologous vessel-derived
ovine endothelial cells and smooth muscle cells. To sim-
ulate a biomimetic environment during tissue formation,
the constructs were grown for varying time points in an
in-vitro pulse duplicator system under gradually increasing
ﬂow and pressure conditions while controls were grown in
staticnutrientmedium.After14daysofin-vitroculture,the
constructs (valves) grown in the bioreactor showed signiﬁ-
cantly increased DNA content, higher formation of matrix
proteins, a more organized histological structure, and more1808 K. MENDELSON AND F. J. SCHOEN
TABLE 4. Representative, animal, and clinical implant studies using seeded and non-seeded matrices.
Study Scaffold Cells Site
In-vitro seeding
(A) Shinoka (1995–96) Polyglycolic acid (PGA) Autologous ovine endothelial
cells and ﬁbroblasts
Replacement of one pulmonary
valve (PV) leaﬂet in sheep
(B) Hoerstrup (2000) Poly-4-hydroxybutyrate (P4HB)
coated PGA
Autologous ovine endothelial
cells and myoﬁbroblasts
Replacement of all three PV
leaﬂets in sheep
(C) Steinhoff (2000) Decellularized pulmonary sheep
valves
Autologous ovine endothelial
cells and myoﬁbroblasts
PV conduits implanted into sheep
(D) Dohmen (2002) Decellularized cryopreserved
pulmonary allograft
Autologous human vascular
endothelial cells
Reconstruction of the right
ventricular outﬂow tract (RVOT)
in a human patient
(E) Perry (2003) P4HB coated PGA Autologous ovine mesenchymal
stem cells
In-vitro only, no in vivo
implantation
(F) Iwai (2004) Poly(lactic-co-glycolic acid)
(PLGA) compounded with
collagen microsponge
Autologous endothelial and
smooth muscle cells; w/ and
w/o in-vitro precellularization
Patch implant in canine
pulmonary artery
(G) Sutherland (2005) PGA and poly-L-lactic acid
(PLLA)
Autologous ovine mesenchymal
stem cells
Replacement of all three PV
leaﬂets in sheep
In-vivo only (No in-vitro seeding)
(A) Matheny (2000) Porcine small intestinal
submucosa
N/A Replacement of one PV leaﬂet in
ap i g
(B) Elkins (2001) Decellularized (using SynerGraft
treatment) human (CryoValve
SG) and sheep pulmonary
valves
N/A SynerGraft-treated and
cryopreserved sheep PVs
implanted in RVOT in sheep;
CryoValve SG human PVs
implanted in patients
(C) Simon (2003) Decellularized porcine Synergraft
valve
N/A Implanted in RVOT in children
favorable mechanical properties than did constructs grown
under static culture conditions. Based on these preliminary
in-vitrostudies,seededconstructsthathadbeenmaturedin-
vitrointhebioreactorfor14dayswereimplantedin-vivoas
a pulmonary valve replacement in an ovine animal model.
After 20 weeks in vivo, the polymer had been degraded and
replaced by a partially endothelialized uniform, layered tis-
sue with layer-speciﬁc ECM predominance similar to that
ofthenative valve, including alayer containing elastinnear
the inﬂow surface, gylcosaminoglycans centrally, and a ﬁ-
brouslayerwithabundantcollagenneartheoutﬂowsurface.
Mechanical properties were comparable to those of native
tissue at 20 weeks.52 Particularly exciting was the presence
of a trilaminar structure resembling the native pulmonary
valve, which indicates that dynamic growth, remodeling,
and asymmetric structural differentiation had occurred in-
vivo, probably regulated by the mechanical environment.
Building on these principles, an autologous trileaﬂet
heart valve was created from a biodegradable synthetic
scaffold [PGA and poly-L-lactic acid (PLLA)] seeded with
autologous bone marrow-derived MSCs. The cell-scaffold
construct was cultured in-vitro then implanted into the pul-
monary artery position of sheep for up to 8 months. The
results showed that the construct remodeled in-vivo to a
tissue with features that simulated those of native valves. In
particular, the tissue-engineered valves displayed a trilami-
nardistributionofcellsandECM,analogoustothoseofna-
tivevalves–myoﬁbroblastsimmediatelybelowtheendothe-
lium, ﬁbroblasts expressing vimentin distributed through-
out the remainder, and endothelialization. These ﬁndings
support the potential use of bone marrow derived MSCs as
acellsourceforthefabricationofheartvalves.Theeditorial
accompanying this paper emphasized that, although proof-
of-concept has been demonstrated based on remodeling of
the construct to a trilaminar structure following implanta-
tion, there remain numerous challenges to overcome before
such technology can be used in human patients.6
Implant Studies Using Biologic Scaffolds Seeded In-Vitro
An especially attractive concept is that of a na-
tive valve biological scaffold, either decellularized
xenograft28,72,141,163 orallograft,thathasbeenseededwith
autologous cells in-vitro.10,158 One study suggested that al-
logenic decellularized sheep matrix conduits seeded with
autologous myoﬁbroblast and endothelial cells may yield
viable valves. Following almost complete removal of cells,
control unseeded allogenic acellular valves implanted in
sheep for up to 3 months showed partial degeneration and
nointerstitialtissuereconstitutionwhereasthecounterparts
seeded with autologous vascular wall cells were reported toHeart Valve Tissue Engineering 1809
show restitution of the endothelial cell surface, myoﬁbrob-
lasts, and matrix synthesis.162
Owing to the antigenicity of xenograft ECM proteins,
xenograft scaffolds likely provide a more inﬂammatory
stimulus than allograft scaffolds, exempliﬁed by the cry-
opreserved homografts presently used clinically.131 An in-
ﬂammatory reaction could weaken or scar the heart valve
scaffold,makingitmoresusceptibletobiomechanicaldam-
age. Therefore, human allograft heart valves, either decel-
lularized or not, have been considered as an alternative
scaffold. Presently used cryopreserved allograft valves are
effectively decellularized following several months of in-
vivo function, yet they do not grow, remodel, exhibit active
metabolic functions, or recellularize, even following long-
term function.95 Moreover, decellularization may alter the
physical properties of native valves and newly seeded cells
may initially have difﬁculty growing into a decellularized
matrix.
HARNESSING THE REPARATIVE POTENTIAL
OF CIRCULATING ENDOGENOUS CELLS:
UNSEEDED SCAFFOLDS
As discussed in the previous section, the basic paradigm
of tissue engineering uses a cell seeded scaffold, an in-vitro
stage of tissue formation, and an in-vivo stage of tissue
growth and remodeling (see Fig. 2, Pathway A). In this
section, we examine an alternative pathway (see Fig. 2,
Pathway B) in which an unseeded scaffold could have the
potential for attracting circulating precursor cells (endothe-
lial and mesenchymal) in-vivo (Fig. 3).
Accumulating evidence suggests that circulating en-
dogenouscellscanberecruitedin-vivotoadheretointravas-
cularsitesviaapathwaythatlikelymimicstheadherenceof
inﬂammatorycellstotheendotheliumduringphysiological
inﬂammation.73 EPCs promote endothelial regeneration in
dog models by covering implanted Dacron grafts149 and in
human studies by covering the blood-contacting surfaces
of implanted ventricular assist devices,40,126 and homing
to stents that have been coated with CD34 antibody (a
marker found on EPCs).3 Recent studies have suggested
therapeutic potential of EPCs in humans.125 Ischemic heart
disease patients with naturally higher levels of EPCs had a
reduced risk of death from cardiovascular causes.180 Fol-
lowing experimental myocardial infarction, bone marrow
derived cells are recruited by selective homing to the area
of injury.98 It has been suggested that intracoronary in-
fusion of EPCs in patients with acute myocardial infarc-
tion might potentially contribute to restoring myocardial
and endothelial function to the damaged area.109 Endoge-
nous stimuli such as tissue ischemia and exogenous cy-
tokines promote mobilization of EPCs.18 Patients with vas-
cular trauma such as acute myocardial infarction display
increased numbers of EPCs, which is positively corre-
lated to elevated plasma VEGF.165 VEGF and other an-
giogenic growth factors such as angiopoietin-1, ﬁbroblast
growth factor and stromal cell-derived growth factor-1 pro-
mote EPC mobilization and recruitment.172 One potential
strategy may be to coat a scaffold with appropriate cell-
signalingmoleculesinanefforttoencourageEPCadhesion
and differentiation. An experiment utilizing decellularized
porcine aortic valves containing ﬁbronectin and hepatocyte
growth factor suggested that the growth factor enhances
early endothelial cell recruitment and coverage of the
grafts.108
Recentexperimentalevidencesuggeststhathumanbone
marrow may be a source of progenitor cells contributing
smooth muscle-like cells to adult human heart valves.23,157
Like endothelial cells, smooth muscle cells can also be
recruited to sites of vascular injury.82,138 Experimental evi-
dence in mouse models suggests that bone marrow derived
smoothmusclecellsmaybeimplicatedindegenerativeaor-
tic stenosis167 and atherosclerosis.135,137,138,139 Evidence
of smooth muscle cell recruitment is exempliﬁed by a pro-
totype tissue-engineered vascular graft. In an experiment
in which rat arteries were acellularized, recellularized with
endothelial cells, and implanted as grafts in the femoral
arteryforfourweeks,immunohistochemicalstainingofex-
planted grafts demonstrated a complete layer of endothelial
cells on the luminal surface and smooth muscle cell re-
population. Since smooth muscle cells were not originally
seeded onto the graft, the authors suggested that they were
recruitedtothegraftfromthebonemarrowbyamechanism
that involved endothelial cells.13
Unseededscaffoldshavebeenexaminedexperimentally,
with the goal of achieving in-vivo recellularization by cir-
culating endogenous cells. In one experiment, each of four
pigs had one pulmonary valve leaﬂet excised and replaced
with a leaﬂet constructed from porcine SIS. Histology indi-
cated that the implanted matrix was progressively resorbed
and replaced by ﬁbrous connective tissue that had features
of adult valve.89 Alternatively, a biodegradable graft con-
taining collagen microsponge was fabricated and tested
with and without preseeding.60 In both cases (SIS and col-
lagen microsponge) there was no thrombus formation, the
scaffold was absorbed, and there was endothelialization,
parallelsmoothmusclecellalignment,elastin,andcollagen
ﬁbers. These results suggested that the patch promoted in-
situ cellularization and regeneration of autologous tissue.
However, an important limitation of these studies was that
the implanted leaﬂets and patches were small; cellulariza-
tion of a large implant may be less efﬁcient.
CLINICAL STUDIES USING ENGINEERED
MATRICES AS HEART VALVES
In this section we examine the limited number of studies
using engineered matrices in clinical settings. One study
used a decellularized pulmonary allograft seeded with au-
tologous endothelial cells and conditioned in bioreactor to1810 K. MENDELSON AND F. J. SCHOEN
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FIGURE 3. A representative hypothesis for the population of a tissue engineered heart valve by endogenous cells. Key pro-
cesses include proliferation, differentiation, and mobilization of endothelial progenitor cells within the bone marrow, followed by
recruitment in the blood and adhesion to the valve. Subsequently, recruited cells might undergo an epithelial to mesenchymal
transdifferentiation within the valve (recapitulating development), followed by differentiation to interstitial cells that ultimately
synthesize and remodel the ECM.
reconstruct the right ventricular outﬂow tract of adults un-
dergoing the Ross procedure.29 According to the investiga-
tors,basedonaone-yearfollow-up,seededendothelialcells
remained on theconstruct and were fullyfunctional and the
construct mechanical strength was maintained. There was
no calciﬁcation and/or thrombogenesis. However, whether
the seeded cells contributed to valve function is yet uncer-
tain.
Despite promising results in animal experiments using
decellularized xenograft scaffolds, translation to humans
has been difﬁcult. Clinical applications of implanted de-
cellularized xenograft tissue heart valves have been largely
unsuccessful.156 Histologicalexaminationofdecellularized
porcine aortic SynerGraft valves (Cryolife Inc.) implanted
for6monthsinsheepwithoutin-vitropreseedingsuggested
some growth of host cells on intact leaﬂets and showed a
lack of calciﬁcation.32 Simon et al. used SynerGraft de-
cellularized porcine heart valves as valve replacements in
the right ventricular outﬂow tract during Ross procedures
in children. The decellularized valves were not seeded or
conditioned in a bioreactor before implant with the hope
that the unseeded scaffold could attract endogenous cells.
Thesevalveshadahighrateoffailure;examinationoffailed
valves revealed incomplete initial decellularization, lack
of cell repopularization, lack of endothelialization, severe
inﬂammation, ﬁbrous sheath formation, calciﬁcation and
severe degeneration of both leaﬂets and wall.156 A recent
report showed a case with inﬁltration of a Synergraft valve
by inﬂammatory cells (neutrophils and macrophages) at
5 weeks post implantation.140
CHALLENGES FOR FUTURE TRANSLATION
TO THE CLINIC
Heart valve tissue engineering has exciting potential but
many unanswered questions and challenges remain before
human implantation can be considered. A successful tis-
sue engineered valve must be vital, complex, dynamic,
composed of specialized cells and ECM that remodel in
response to changes in local mechanical forces, and have
ongoingstrength,ﬂexibility,anddurability,beginningatthe
instant of implantation and continuing indeﬁnitely there-
after. A schema for the interrelationships among and chal-
lenges in tissue characterization for heart valve tissue en-
gineering is summarized in Fig. 4. To provide an agenda
fortranslatingthenotionofTEHVsfromanextraordinarily
interesting research curiosity to a clinically useful surgical
tool, we discuss below both the major research goals—i.e.,
understandingmechanisms,deﬁninganimalmodels,devel-
oping biomarkers, developing assays/tools, deﬁning surro-
gate and true endpoints—and the major clinical goals—
i.e., characterizing and assuring quality tissue constructs,
accommodating patient-to-patient heterogeneity in tissue
remodeling, and predicting outcomes as early as possible.
Numerous steps must be surmounted in the laboratory
beforeheartvalvetissueengineeredconstructscanbemade
clinically useful. Typical biomaterial-tissue interactions in
medical devices, such as thrombosis, infection, and inﬂam-
matory interactions, will have to be acceptable. Another
important consideration is whether calciﬁcation, the ma-
jor pathologic process in bioprosthetic valve degeneration,Heart Valve Tissue Engineering 1811
TABLE 5. Critical challenges to clinical translation of heart valve tissue engineering.
Challenges Strategy for translation
TEHV components and function are complex, heterogeneous and
dynamic
Develop guidelines for the pre-implantation characterization of TEHV
structure, function and quality
TEHV function depends upon patient response to implantation and
integration with the recipient’s tissues more than conventional
valve replacement
Identify/validate biomarkers predictive of implant success/failure and
capable of non-invasive in-vivo monitoring
Individuals differ in the speed and effectiveness of their tissue
remodeling
Assess/control patient variability in tissue remodeling capability
Owing to the key role of patient response, animal models may not
reliably predict human outcomes
Validate suitable animal models that will test key biological
processes and correlate with human outcomes
Remodeling processes after implantation may release or change
seeded cells and recruit host cells
Develop tools to monitor the fate of transplanted and endogenous
cells (location, function, viability, phenotype)
will be problematic. Evidence suggests that calciﬁcation
may not be a major problem as long as polymer or other
scaffold is resorbed and/or not intrinsically mineralizable,
the interstitial cells are viable, and the ECM is capable of
remodeling.
While studies using animal models such as sheep are
promising, further detailed studies will be needed in these
models, other animal models, and in humans. There is con-
siderablecontroversyovertowhatextentresultsfromavail-
able animal models translate directly to humans and the
most suitable animal model for testing tissue-engineered
valves has not yet been determined. Sheep for example,
produce an exuberant ﬁbrotic response to cardiovascu-
lar implants; valves implanted in sheep generally over-
grow more rapidly with ﬁbrotic tissue than they do in hu-
mans, and likely overestimate tissue remodeling relative
to humans.144 Owing to immunologic considerations, the
choice of an animal model for preclinical testing for allo-
genic or xenogeneic cell-based therapies presents unique
challenges.
A key consideration is that currently available heart
valve replacements have predictable behavior in many re-
cipients whereas in-vivo remodeling of tissue engineered
heart valves will likely display considerable variability
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FIGURE 4. Paradigm for translating research in heart valve tissue engineering from the laboratory to the clinic. Biomarkers for
cell and tissue characterization in conjunction with structural, chemical and molecular information obtained via in-vitro and in-
vivo models are necessary for understanding key biological processes in tissue engineering and regenerative medicine. These
concepts and data can be used to predict and measure patient success and failure. Data from clinical experience further informs
the development of appropriate biomarkers, which may result in reassessment of the appropriate characterization parameters.1812 K. MENDELSON AND F. J. SCHOEN
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FIGURE 5. A hypothesis for inter-individual variability in tis-
sue remodeling. While most individuals will remodel tissue
with a usual speed and quality of remodeling, some people
will display slow and poor quality of remodeling while others
will show fast and better quality of remodeling. Inadequate re-
modeling could lead to implant failure and its consequences
for the patient. The threshold of properties needed for tissue
engineered heart valves and the means of conducting post-
implantation surveillance of the patient and graft need to con-
sider this variability. Success or failure may be followed and
predicted non-invasively.
among patients, owing to heterogeneity among individu-
als in physiological tissue remodeling potential. As the
ﬁeldoftissueengineeringevolvesitmaybecomeimportant
to apply principles analogous to those of pharmacogenet-
ics, a ﬁeld which seeks to understand the role of genetics
in inter-individual variation in drug metabolism.179 Sim-
ply stated, some patients might not appropriately remodel
their tissue-engineered valves, and this could lead to failure
(Fig. 5). This could be a result of mutations or polymor-
phisms in key proteins central to remodeling.11,24,38,91 In-
deed,asimplantshavebecomemoreinteractiveandintegra-
tive with the host tissues, there has arisen a corresponding
need to understand and potentially control human variation
in different facets of biomaterial-tissue interaction and the
healing process. To accommodate TEHVs, the usual mech-
anism for demonstrating pre-clinical safety and efﬁcacy of
medicaldevicesandbiologicsmayneedtobealtereddueto
unpredictabilityoftheengineeredtissuewiththerecipient’s
native tissue.
To understand, monitor, and potentially control patient-
to-patient differences in wound healing and tissue remod-
eling capability in-vivo, biomarkers that predict implant
outcomes must be identiﬁed. Conventional and innovative
invasiveand/ornon-invasiveanatomicandfunctionalimag-
ing modalities will certainly be important tools to assess
success and failure. Speciﬁc molecular biomarkers may be
identiﬁed and validated by assessing tissue healing and re-
modeling during in-vitro and in-vivo experiments; suitable
biomarkers will need to be followed in-vivo, possibly via
chemicalassaysintheserumorurineorviamolecularimag-
ing. Key targets for characterizing tissue-engineered con-
structs include tissue composition, cellular gene expression
and phenotype, ECM, key effectors of tissue remodeling
and tissue quality. For example, researchers are currently
working to identify serum-speciﬁc biomarkers of ECM re-
modeling in disease such as MMPs in acute coronary syn-
dromes,4,42 and urine-based biomarkers for cancers of the
breast,39,136 bladder,49,175 andprostate.55 Thesebiomarkers
should correlate directly with success and failure in order
to generate surrogate endpoints, namely outcome measure-
ments (such as laboratory assays or imaging results) that
substituteforbutreﬂectthemechanismofasigniﬁcantclin-
ical event or characteristic (such as regurgitation, stenosis,
thromboembolism, calciﬁcation, infection, or death). Vali-
dated surrogate end points could be assessed in an individ-
ual patient, in order to predict outcome as early as possible
in the patient’s course and inﬂuence necessary changes in
management.
Thepotentialformolecularimagingisparticularlyexcit-
inginthisregard;itrequirestheidentiﬁcationofamolecular
target,selectionofaligandthatbindsthetarget,selectionof
anappropriateimagingsystem,andsynthesisofamolecular
imaging agent to detect the desired target.8,44,57,62,63 In-
vivo molecular imaging has been used to demonstrate key
enzymatic and cellular events in atherosclerosis and throm-
bosis.Forexample,imagingstudiesoninﬂammatorymark-
ers such as proteases (cathepsins and MMPs), activated
macrophages (expressing iron oxide), and activated en-
dothelium (intercellular and vascular adhesion molecules)
have been performed in atherosclerotic mice.19,24 Molec-
ular imaging can probe polymorphisms of ECM gene ex-
pression in-vivo in models of cardiovascular disease,12,105
and can potentially be translated to perform real-time in-
vivo characterization of scaffold matrices (either seeded or
withthepotentialofattractingendogenouscells)implanted
in animal models. Other imaging modalities such as op-
tical coherence tomography (OCT)15,47 and intravascular
ultrasound (IVUS)111 have been used to assess collagen
content of coronary atherosclerotic plaque; allowing real-
timein-vivoanalysiswithouttissuesampling.Suchimaging
modalities may prove useful in assessing tissue remodeling
for heart valve tissue engineering applications.
Another important laboratory consideration for seeded
scaffolds is the origin of the cells seeded in-vitro and
whether the seeded cells remain viable and attached to the
scaffold following in-vivo implantation. In the absence of
in-vitro cell labeling, it is not possible to ascertain the fate
of preseeded cells and the precise origin of the cellular
phenotypes observed in the explanted tissue engineered
valves. Molecular imaging could be utilized to track the
presence, migration, proliferation, and function of bone
marrow derived progenitor cells used to seed scaffolds both
in-vitro and in-vivo.62,63 Moreover, molecular resonance
imaging (MRI) of magnetically labeled mesenchymal stem
cells injected into porcine myocardium has been performed
in-vivo,51 a technique which can potentially be expanded to
study magnetically labeled endothelial and mesenchymal
progenitor cells seeded on a scaffold and implanted into anHeart Valve Tissue Engineering 1813
animal or human model. In future experiments, endothelial
progenitor and mesenchymal stem cells might be labeled
during the in-vitro stage and then analyzed using molecular
imaging to ensure that they differentiate into appropriate
cell lineages and that they remain functional and attached
to the scaffold over time.
There is a need to develop clinical guidelines that spec-
ify how to characterize the safety, efﬁcacy, and quality of a
tissue engineered product before it can be implanted in hu-
mans. Demonstration of long-term efﬁcacy (implantability,
functionality, long-term performance) and safety (biocom-
patibility, durability, modes of failure, ease of monitoring)
of these valves in humans will be a particular challenge.
Risk/beneﬁt relationships of engineered tissue may be less
predictable than those of accepted technology. Since con-
temporary heart valve replacements have considerable suc-
cessinmostsituations(notwithstandingthelimitations,and
except in pediatrics), acceptance of tissue engineering by
the surgical community may be slow. It has been suggested
that surgeons will consider the use of a tissue-engineered
valve in a patient beyond appropriately controlled clinical
research only after the 15-year lifetime of conventional
valve substitutes can be exceeded with a high degree of
certainty.128
Another key need is the development of science-
based approaches to the characterization of fabri-
cated/manufactured engineered tissue products in general
andheartvalvesinparticular.Thesewilllikelyincludemea-
surement of mechanical properties of the scaffold and the
tissue-scaffold complex, characterization of the dynamic
cell phenotypes and ECM components, and the evolution
of the ﬁnal manufactured product, including shelf-life, sta-
bility, and shipping considerations.
CONCLUSIONS
The goal of heart valve tissue engineering is to regener-
ate a functional structure containing endothelial and inter-
stitial cells capable of continuously remodeling the ECM
that functions structurally and biomechanically as a valve
leaﬂet. Despite an exciting potential for tissue engineered
heart valves, signiﬁcant technical barriers must be over-
come before widespread clinical application can be envi-
sioned. Further success toward a clinically useful tissue
engineered heart valve will be dependent upon additional
advances in biodegradable polymers, stem cell manipula-
tion, strategies for recreating the ECM, understanding how
to harvest the potential of endogenous recruitment of cells,
and techniques to non-invasively assess the speed and qual-
ity of tissue healing and remodeling. This need is likely
to engender a host of novel testing strategies and methods,
which will include in-vitro safety studies, ex-vivo perfor-
mance characterization in functional testing devices akin to
bioreactors, and in-vivo preclinical studies.
NOTE ADDED IN PROOF
Severalstudiesrelevanttoandthatbecameavailabledur-
ingﬁnalproductionofthismanuscriptmayinterestreaders.
Visconti, R.P., Y. Ebihara, A.C. LaRue, P.A.
Fleming, T.C. McQuinn, M. Masuya, H. Minamiguchi,
R.R. Markwald, M. Ogawa, and C.J. Drake. An in-
vivo analysis of hematopoietic stem cell potential:
hematopoietic origin of cardiac valve interstitial cells.
Circ. Res. 98:690–696, 2006.
To test the hypothesis that hematopoietic stem cells
(HSC) may be a source of adult valve interstitial cells,
single lineage-negative (Lin-), c-kit(+), Sca-l(+), CD34-
cells from the bone marrow of mice that ubiquitously
express enhanced green ﬂuorescent protein (EGFP) were
transplanted into a lethally irradiated congenic non-EGFP
mouse. Histological analyses of valve tissue from clonally
engraftedrecipientmicerevealedthepresenceofnumerous
EGFP+ cells within host valves, some of which exhibited
syntheticpropertiescharacteristicofﬁbroblasts(expression
of mRNA for procollagen 1 alpha 1). The cells were shown
to be the result of HSC-derived cell differentiation and
not fusion with host somatic cells. Together, these ﬁnd-
ings demonstrate a contribution by HSCs to the adult valve
interstitial cell population in mice.
Cao, F., S. Lin, X. Xie, P. Ray, M. Patel, X. Zhang,
M. Drukker, S.J. Dylla, A.J. Connolly, X. Chen, I.L.
Weissman,S.S.Gambhir,andJ.C.Wu.Invivovisualiza-
tion of embryonic stem cell survival, proliferation, and
migration after cardiac delivery. Circulation 113:1005–
1014, 2006.
Asdiscussedinthebodyofthepresentmanuscript,mon-
itoring the trafﬁcking and function of stem cells in vivo
remains problematic owing to limitations of conventional
histological assays and imaging modalities. A recent study
demonstratedamethodbywhichembryonicstem(ES)cells
could be stably transduced with a lentiviral vector carrying
anoveltriple-fusion(TF)reportergene,trackedbypositron
emission tomography, and monitored for survival, prolifer-
ation, and migration. This imaging platform should have
broad applications for basic research and clinical studies
on stem cell therapy.
Kiernan, T.J. Endothelial progenitor cells in 2006 –
where are we now? Cardiovasc. Pathol. 15:236–239,
2006.
A recent brief review of the current status of endothelial
progenitor cells (EPCs), including their role as biomarkers
and potential therapeutic applications, may be useful to the
reader of the present manuscript. The authors emphasize
critical questions relating to the characterization of the bi-
ological phenotype of “true” EPCs and the mechanisms
of interaction of EPCs with resident cells of the vascular
wall.1814 K. MENDELSON AND F. J. SCHOEN
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